We were originally created to exploit the 3S/P44L platform and mechanism of actions in the treatment of HIV.

Today, our science has broad applications in the field of infectious diseases and oncology

our science

VAC-3S VAC-3S has demonstrated its ability to produce anti-3S antibodies in a clinical meaningful way in 52% of patients treated in phase 1 and phase 2 clinical studies. Vaccine safety is confirmed in the 131 patients treated in these studies.

VAC-02 These results open therapeutics application opportunities beyond vaccinology and HIV in the field of infectious diseases.

P44-L P44-L is curently in validation in various disease models of oncology for CAR-T and CAR-NK development.

contact

28 rue de l'Amiral Hamelin 75016 Paris

Alain Maiore

chairman et CEO

Delphine joyeux

COO
*Champs obligatoires